The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia

The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia

Autor Oppezzo, P. Google Scholar
Vasconcelos, Yuri Autor UNIFESP Google Scholar
Settegrana, C. Google Scholar
Jeannel, D. Google Scholar
Vuillier, F. Google Scholar
Legarff-Tavernier, M. Google Scholar
Kimura, Eliza Yuriko Sugano Autor UNIFESP Google Scholar
Bechet, S. Google Scholar
Dumas, G. Google Scholar
Brissard, M. Google Scholar
Merle-Beral, H. Google Scholar
Yamamoto, Mihoko Autor UNIFESP Google Scholar
Dighiero, G. Google Scholar
Davi, F. Google Scholar
French Cooperative Grp CLL Google Scholar
Instituição Hop La Pitie Salpetriere
Inst Pasteur
Universidade Federal de São Paulo (UNIFESP)
Resumo Although the zeta-associated protein of 70 kDa (ZAP-70) is overexpressed in patients with chronic lymphocytic leukemia (CLL) displaying unmutated IGVH genes and poor prognosis, a previous microarray study from our group identified overexpression of LPL and ADAM29 genes among unmutated and mutated CLL, respectively. To assess the prognostic value of these genes, we quantified their expression by real-time quantitative polymerase chain reaction (PCR) in a cohort of 127 patients with CLL and correlated this with clinical outcome, IGVH mutational status, and ZAP-70 protein expression. IGVH mutational status, ZAP-70, and the LPL and ADAM29 mRNA ratios (L/A ratio) were predictive of event-free survival for the whole cohort and for patients with stage A disease. in patients in stage B and C, the L/A ratio was an independent prognostic factor, whereas ZAP-70 did not predict survival. Simultaneous usage of the L/A ratio and ZAP-70 expression allowed an almost perfect (99%) assessment of the IGVH status in the 80% of patients with concordant results (L/A(+), ZAP-70(+) or L/A(-), ZAP-70(-)). LPL and ADAM29 gene expression could also be determined by a simple competitive multiplex reverse transcription PCR assay. Overall, quantification of LPL and ADAM29 gene expression is a strong prognostic indicator in CLL, providing better prognostic assessment than ZAP-70 in advanced stages of the disease.
Idioma Inglês
Data de publicação 2005-07-15
Publicado em Blood. Washington: Amer Soc Hematology, v. 106, n. 2, p. 650-657, 2005.
ISSN 0006-4971 (Sherpa/Romeo, fator de impacto)
Publicador Amer Soc Hematology
Extensão 650-657
Fonte http://dx.doi.org/10.1182/blood-2004-08-3344
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000230472100047
Endereço permanente http://repositorio.unifesp.br/handle/11600/28384

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta